Future role of electrical therapy for atrial fibrillation: reality for all?
St. George's Hospital Medical School, London, U.K.
* Correspondence: Professor A. John Camm, Professor of Clinical Cardiology, Department of Cardiological Sciences, St. George's Hospital Medical School, Cranmer Terrace, London, SW17 ORE, U.K.
Abstract
Atrial fibrillation (AF) is a highly prevalent condition with a rapidly growing incidence, especially in elderly patients with underlying heart disease. The arrhythmia can be treated by a vast array of pharmaceutical and non-pharmacological therapies, suggesting that no single treatment is sufficiently simple, successful and cheap to exclude other therapies. Many new therapies are presently being developed, among which are electrical therapies that are designed to prevent and convert AF. Cardiac pacemakers, implantable atrial defibrillators and ablation techniques to modify the behaviour of the atrial myocardium are discussed in this symposium. Some of the specific techniques have been shown to be valuable in case reports, small case-matched series and small randomized clinical trials. The technology associated with these techniques is still in a developmental stage, however, and cannot yet be widely assessed from a practical clinical perspective. Extensive clinical implementation will require demonstration of clinical efficacy, feasibility and cost-benefit before it is possible to argue for the increased resources that will be necessary to fund widespread use of electrical treatments for the management of AF.
Key Words: Atrial defibrillator • pacemaker
References
- Ryder KM, Benjamin EJ. Epidemiology and significance of atrial fibrillation. Am J Cardiol. 1999;84:131R–138R[CrossRef][Web of Science][Medline]
- The Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The ‘Sicilian Gambit’. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Eur Heart J. 1991;12:1112–1131
[Abstract/Free Full Text] - The search for novel antiarrhythmic strategies. Sicilian Gambit. AnonymousEur Heart J. 1998;19:1178–1196
[Free Full Text] - Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376–380
[Abstract/Free Full Text] - Brugada R, Tapscott T, Czemuszewicz GZ, et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med. 1997;336:905–911
[Abstract/Free Full Text] - Bode F, Katchman A, Woosley RE, Franz MR. Gadolinium decreases stretch-induced vulnerability to atrial fibrillation. Circulation. 2000;101:2200–2205
[Abstract/Free Full Text] - Stafford PJ, Kolvekar S, Cooper J, et al. Signal averaged P wave compared with standard electrocardiography or echocardiography for prediction of atrial fibrillation after coronary bypass grafting. Heart. 1997;77:417–422
[Abstract/Free Full Text] - Skanes AC, Krahn AD, Yee R, et al. Canadian Trial of Physiologic Pacing. Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. CPOPP Investigators. J Am Coll Cardiol. 2001;38:167–172
[Abstract/Free Full Text] - Wellens FU, Lau CP, Luderitz B, et al. Atrioverter: an implantable device for the treatment of atrial fibrillation. Circulation. 1998;98:1651–1656
[Abstract/Free Full Text] - Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659–666
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||